AI Spatial Biology startup Nucleai secured $33 Million in Series B Round

Nucleai, an Israel based AI-powered spatial biology company, has now secured $33 million in a Series B funding round.

Nucleai is founded by Avi Weidman. It offers pharmaceutical companies, contract research organizations, diagnostics laboratories with an AI platform to improve clinical trials and clinical decision making.

The platform is used for retrospective and prospective patient satisfaction analysis in clinical trials, driving improvement of the probability of success and improved patient outcomes.

Avi Veidman, CEO of Nucleai, said, "Nucleai’s vision is to bring spatial biology to the forefront of precision medicine and to embed the use of our platform in every clinical trial involving tissue over the next few years. We are pleased to bring world-class investors who share our passion and vision to transform drug development and clinical treatment decisions by combining artificial intelligence, big data, spatial biology, and a comprehensive software platform."

Cris De Luca, Global Head, Digital Investments at Sanofi Ventures, said, "The rapid growth and achievements of the Nucleai team have them well-positioned to be spatial biology platform leaders, transforming current approaches to pathology. By harnessing artificial intelligence with spatial data and other data modalities, Nucleai is enabling researchers and clinicians to make better treatment decisions for patients based on a comprehensive, holistic view of cellular locations, interactions, and the tumour microenvironment."

The round was backed by Sanofi Ventures and Section 32 with participation from Debiopharm, Vertex Ventures, Fosun RZ Capital, and Grove Ventures.

The company, as of now, has plans to use the new funds to further develop its platform and expand its commercial footprint across the biopharmaceutical companies and contract research organizations (CROs), who are applying its technology throughout translational research, novel applications and clinical trials for drug discovery.